Drug Trial Radar · NCT07929350
Fuling Yunhua Granules and Dihuang Baoyuan Granules in Adults With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Therapy
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Nov 20, 2026
Primary completion
Jan 15, 2028
Study completion Mar 15, 2028
Sponsor
- Lead sponsor
- Beijing Supreme Life Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial tests whether Fuling Yunhua Granules and Dihuang Baoyuan Granules, given in sequence with or without continued metformin, lower blood sugar in adults with type 2 diabetes already taking metformin. It will also assess their safety.
Conditions
- Diabetes Mellitus, Type 2
Interventions
Fuling Yunhua GranulesDrug
Traditional Chinese herbal medicine granules, 12 g per bag, taken orally before meals.
Dihuang Baoyuan GranulesDrug
Traditional Chinese herbal medicine granules, 18 g per bag, taken orally before meals.
Fuling Yunhua Granules Matched PlaceboDrug
Matched placebo for Fuling Yunhua Granules; identical in appearance (shape, color and packaging), odor and taste, but containing no active herbal components. Granules, 12 g per bag, taken orally before meals.
Dihuang Baoyuan Granules Matched PlaceboDrug
Matched placebo for Dihuang Baoyuan Granules; identical in appearance (shape, color and packaging), odor and taste, but containing no active herbal components. Granules, 18 g per bag, taken orally before meals.
MetforminDrug
Oral biguanide antihyperglycemic agent, 0.5 g per tablet, taken orally as stable background therapy throughout the study.
Metformin Matched PlaceboDrug
Matched placebo for metformin; identical in appearance (shape, color and packaging) to metformin tablets, but containing no active pharmaceutical ingredients. Tablets, 0.5 g per tablet, taken orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Glycated Hemoglobin (HbA1c) at Week 24Time frame: Baseline and Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.